Reports
Human Milk Oligosaccharides(HMO) Market Analysis Report,2026-2034
REPORT DETAILS
REPORT DETAILS
ABOUT THIS REPORT
Market Statistics
Human Milk Oligosaccharides (HMO) Market Overview
The global human milk oligosaccharides market size was valued at USD 292.09 million in 2025. The market is projected to exhibit a CAGR of 22.60% during 2026–2034. The rising demand for infant nutrition and increased focus on personalized nutrition are a few of the key factors shaping the market landscape.
Key Takeaways
- Asia Pacific held the largest share of 52.4% in 2025, driven primarily by the region's growing population and increasing birth rates.
- The Middle East & Africa is projected to experience rapid growth at a 27.5% CAGR, due to the rising awareness of infant health and nutrition.
- The 2’FL segment dominated the market with a 56.8% revenue share in 2025, owing to the extensive use of 2'FL in infant nutrition.
- The hypermarkets & supermarkets segment is expected to register a robust CAGR of 23.2% during the projection period, driven by rising consumer preference for convenient, in-store shopping experiences.
- The infant formula segment led with a 73.4% revenue share in 2025, owing to the growing global demand for infant nutrition products.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
Market Statistics
- 2025 Market Size: 292.09 Million
- 2034 Projected Market Size: 1,821.29 Million
- CAGR (2026–2034): 22.60%
- Asia Pacific: Largest Market in 2025
Industry Dynamics
- Consumers are increasingly seeking alternatives to breastfeeding. This has led to higher demand for infant formulas that replicate the benefits of natural breast milk.
- The rising focus on immunity and gut health has created an increased need for prebiotics and probiotics. HMO plays a key role in both the categories.
- The utilization of advanced biotechnology to produce HMO at scale is expected to present several market opportunities.
- High production costs and complex manufacturing processes may limit market expansion
The human milk oligosaccharides (HMO) market has experienced significant growth in recent years, driven by a rising awareness of the crucial role human milk oligosaccharides (HMO) play in infant nutrition and overall health. Human milk oligosaccharides (HMO) are complex carbohydrates found in human breast milk, known for their ability to support the immune system, enhance gut health, and promote the growth of beneficial bacteria in infants. As research continues to highlight the numerous benefits of these oligosaccharides, both in infant nutrition and beyond, the demand for HMO-enriched products is surging across the globe. This trend is being further fuelled by innovations in the production and application of human milk oligosaccharides in various food, beverages, and pharmaceutical industries.
The HMO market development is attributed to the growing demand for infant formula that mimics the benefits of breast milk. With more parents seeking alternatives to breastfeeding, HMO-enriched formulas are gaining traction due to their potential to improve gut microbiota, strengthen immunity, and reduce the risk of infections in infants. Additionally, increasing health consciousness among consumers and a shift toward functional foods and prebiotics have amplified the appeal of human milk oligosaccharides (HMO) as essential ingredients in gut health supplements. Furthermore, advancements in biotechnological methods for HMO production, such as fermentation-based processes, are lowering production costs and facilitating the introduction of HMO-based products into new markets.
 Market analysis.png)
To Understand More About this Research: Download Sample Report
One notable HMO market trend is the growing focus on personalized nutrition, with human milk oligosaccharides being increasingly incorporated into products tailored to the specific health needs of consumers. Additionally, the expansion of HMO applications beyond infant nutrition—into areas such as adult digestive health, immunity support, and skincare—further broadens the market’s potential. Regulatory support for functional ingredients and the rising demand for plant-based and clean-label products are also expected to drive the human milk oligosaccharides market growth, making it an attractive segment for new and established players in the health and wellness industry.
Human Milk Oligosaccharides (HMO) Market Dynamics
Growing Demand for Infant Nutrition
As consumers increasingly seek alternatives to breastfeeding, there is a rising demand for infant formulas that replicate the benefits of natural breast milk. Human milk oligosaccharides support immune function, gut health, and cognitive development, which are critical for infant development. Their inclusion in infant formula helps address the nutritional gaps for infants who cannot be breastfed, making them a vital component in modern-day infant nutrition. Furthermore, the trend toward premium and functional infant formulas enriched with HMO is driven by a desire to offer infants the best possible start in life. This demand is particularly strong in regions with high working-mother populations, where breastfeeding rates may be lower, increasing the reliance on formula-based feeding. Therefore, growing awareness regarding the essential role of human milk oligosaccharides in infant health and the rising demand for infant nutrition boost the HMO market development.
Rising Prebiotic and Probiotic Demand
The increasing focus on gut health, immunity, and overall wellness is driving the demand for prebiotics and probiotics, with human milk oligosaccharides (HMO) playing a key role in both categories. Human milk oligosaccharides (HMO) are known to act as prebiotics, promoting the growth of beneficial gut bacteria and contributing to a balanced microbiome. As consumers become more health-conscious and seek natural ways to enhance digestion and immune function, there is growing interest in functional foods and supplements containing HMO. In addition, the rise of probiotic-rich products, often paired with prebiotics for synergistic effects, is encouraging the integration of HMO into a wide range of health supplements. This shift toward digestive health and immunity-boosting products is expected to continue, driving consumer interest in products such as functional foods, dietary supplements, and fortified beverages that support overall well-being. Additionally, as the connection between gut health and other areas of wellness, such as mental health, becomes more evident, the demand for HMO-infused products is likely to rise in the coming years. Thus, the rising demand for prebiotic and probiotic-rich products is expected to provide lucrative HMO market opportunities during the forecast period.
Key Focus Areas of Human Milk Oligosaccharides Market
Prebiotic Components: HMOs serve as prebiotics, facilitating the proliferation of beneficial bacteria in the gut and hence aiding in proper digestion and immunity in infants.
Innovative Infant Formula: HMOs have been included in infant formulas to emulate the effects of breast milk.
Healthy Gut Microbiota: HMOs assist in creating a healthy gut microbiota, which promotes immunity and wellness.
HMO Food Additives: These food additives are becoming common due to their role in facilitating proper digestive processes and enhancing immunity.
Bioactive Substances: HMOs are vital biologically active substances that are used by the body in performing important physiological functions such as developing immunity
 Market10.png)
Human Milk Oligosaccharides Market Segment Insights
Human Milk Oligosaccharides Market Outlook, by Type Insights
The human milk oligosaccharides market, based on type, is segmented into 2’FL, 3’FL, 3’SL, and 6’SL. In 2025, the 2’FL segment dominated the market, accounting for 56.8% of the market revenue share. This dominance is primarily driven by the extensive use of 2'FL in infant nutrition, where it mimics the benefits of natural breast milk. As a primary HMO in human milk, 2'FL has been extensively studied for its positive impact on gut health, immune function, and the development of the infant microbiome. Its ability to support the growth of beneficial bacteria, such as Bifidobacterium, while preventing pathogen adhesion has made it a highly sought-after ingredient in infant formulas, particularly those aimed at providing the closest possible alternative to breast milk.
Increasing awareness related to the importance of infant gut health and immunity is one of the primary drivers of the 2'FL segment growth, with parents and healthcare professionals prioritizing products enriched with 2'FL. Additionally, the growing demand for functional foods and supplements, alongside advancements in production technologies, has made 2'FL more accessible for incorporation into various health and wellness products. Trends toward premium infant formula products and increasing consumer preference for natural and bioactive ingredients further fuel the demand for 2'FL. As the benefits of 2'FL continue to be validated through research, its position as a leading HMO type in the market is expected to strengthen during the forecast period.
| Type | Simple Description | Benefits | Application |
| 2'-FL (2'-fucosyllactose) | Nutrient found in breast milk that builds the baby's immunity. | It builds the immune system and promotes good bacteria. | Baby formulas, nutritional support for babies |
| 3-FL (3-fucosyllactose) | Milk sugar that aids healthy digestion among infants. | It builds good digestion and gut health. | Baby formulas, foods for babies |
| 3'-SL (3'-sialyllactose) | Nutritious compound found in breast milk that promotes brain and immune development. | Beneficial in building early brain development and immunity. | Baby formulas, nutritional supplements for children |
| 6'-SL (6'-sialyllactose) | Milk component that promotes immunity and good gut flora in babies. | It promotes immunity and good digestive processes. | Baby formulas, clinical baby nutrition formulas |
Human Milk Oligosaccharides Market Assessment, by Distribution Channel Insights
The human milk oligosaccharides market segmentation, based on distribution channel, includes hypermarkets & supermarkets, drug store or pharmacy, online sales channel, and others. The hypermarkets & supermarkets segment is expected to register a robust CAGR of 23.2% during the forecast period, primarily driven by the increasing consumer preference for convenient, in-store shopping experiences. As hypermarkets and supermarkets continue to expand their product offerings, including HMO-enriched infant formulas and functional foods, they provide consumers with easy access to a wide range of premium products. Additionally, the physical presence of these retail outlets allows for greater product visibility and the opportunity to influence purchasing decisions through in-store promotions and expert consultations.
The growing middle-class population, particularly in emerging markets, is contributing to the hypermarkets & supermarkets segment growth as consumers seek quality nutrition products from trusted retail brands. Furthermore, these retail channels benefit from efficient supply chain networks, ensuring that HMO-based products are readily available and consistently stocked, which boosts consumer confidence and drives sales growth. The increased focus on health and wellness products by hypermarkets and supermarkets, coupled with rising awareness of the benefits of human milk oligosaccharides (HMO), positions this distribution channel for continued growth.
 Market Seg.png)
Human Milk Oligosaccharides Market Regional Insights
By region, the study provides HMO market insights into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Asia Pacific held the largest share of the human milk oligosaccharides (HMO) market revenue in 2025 accounting for 52.4%, driven primarily by the region's growing population and increasing birth rates, particularly in countries such as China and India. These nations have large infant populations, leading to a high demand for infant formula and nutritional products. The rising awareness of the health benefits of human milk oligosaccharides (HMO), such as improved gut health, enhanced immunity, and cognitive development, is also a significant factor driving the adoption of HMO-enriched infant formulas. As consumers in Asia Pacific become more health-conscious and educated about the importance of early childhood nutrition, the demand for products containing human milk oligosaccharides (HMO) is accelerating.
The expanding middle-class population in countries such as China, India, and Southeast Asia is contributing to the increased demand for premium and functional food products, including HMO-based infant formulas. Consumers are increasingly willing to invest in high-quality nutrition for their children, which drives the human milk oligosaccharides market expansion in the region. Rising disposable incomes and surging urbanization are also promoting the shift toward more convenient retail options, such as supermarkets and online sales channels, where HMO-enriched products are readily available. Moreover, with continuous advancements in the production of human milk oligosaccharides and greater distribution across the region, Asia Pacific is expected to maintain its dominance in the global HMO market during the forecast period.
 Market Reg.png)
North America accounts for the second-largest share of the human milk oligosaccharides (HMO) market revenue due to the increasing demand for premium infant nutrition products. The growing awareness among parents and healthcare professionals about the health benefits of human milk oligosaccharides (HMO), such as immune support and gut health, has driven the adoption of HMO-enriched infant formulas. Additionally, the region has a high number of working mothers, which further contributes to the demand for high-quality, convenient alternatives to breastfeeding.
The rising health consciousness among consumers and an increasing preference for natural and bioactive ingredients in baby food propel the human milk oligosaccharides market expansion in North America. Trends toward personalized nutrition, where human milk oligosaccharides (HMO) are used to cater to specific infant needs, and a rise in e-commerce sales for convenience are also supporting the regional market growth. With continued research validating the benefits of HMO, demand for human milk oligosaccharides is expected to grow in this region during the forecast period.
The Middle East & Africa human milk oligosaccharides (HMO) market is experiencing rapid growth rate of CAGR 27.5% due to the rising awareness of infant health and nutrition. Increased healthcare access and higher disposable incomes are driving demand for premium infant formula enriched with human milk oligosaccharides (HMO). Additionally, the growing trend of health-consciousness among parents, coupled with a shift toward high-quality, bioactive ingredients in baby food, is fueling the adoption of HMO-based products. Urbanization and changing lifestyles also contribute to this market expansion.
Human Milk Oligosaccharides (HMO) Market – Key Players and Competitive Insights
Key players in the human milk oligosaccharides market are making significant investments in research and development to enhance their product portfolios, which is expected to drive market growth in the coming years. Companies are pursuing various strategic initiatives to strengthen their global presence, including new product launches, partnerships, mergers and acquisitions, increased investments, and collaborations with other organizations. To thrive in an increasingly competitive and expanding market, HMO market participants must focus on offering cost-effective solutions while maintaining product quality and innovation.
Product innovation and differentiation coupled with strategic partnerships and collaborations are a few key business tactics used by manufacturers in the global human milk oligosaccharides market to benefit clients. A few major players in the market are Elicityl S.A., Abbott Laboratories, Biosynth Carbosynth, Dextra Laboratories Ltd., Dupont Nutrition & Biosciences, Glycosyn, BASF S.E., Nestle Health Science, Neolacta Lifesciences Pvt. Ltd., Royal DSM, Medolac Laboratories, Chr. Hansen Holding A/S, ZuChem, Inbiose NV, and Royal FrieslandCampina N.V.
Dupont Nutrition & Biosciences is a global company operating in the biotechnology industry. The company offers a broad range of solutions in food, beverages, and nutritional products. Its portfolio includes probiotics, enzymes, and human milk oligosaccharides, which focuses on enhancing gut health and immunity. Dupont HMO products are primarily used in infant nutrition, helping to mimic the benefits of breast milk. Moreover, Dupont's innovative approach to HMO production, utilizing fermentation technologies, supports the growing demand for premium baby formulas.
Chr. Hansen Holding A/S is a global bioscience company specializing in natural ingredients for the food, health, and agriculture sectors. Its business segments include enzymes, and food cultures, focused on human health segment. Chr. Hansen is into the production of human milk oligosaccharides, primarily for use in infant nutrition, supporting gut health and immune development. The company emphasizes sustainability and innovative biotechnology to provide high-quality HMO solutions that meet the growing demand in global markets for infant formulas and health products.
List of Key Companies in Human Milk Oligosaccharides Market
- Abbott Laboratories
- BASF S.E.
- Biosynth Carbosynth
- Chr. Hansen Holding A/S
- Dextra Laboratories Ltd.
- Dupont Nutrition & Biosciences
- Elicityl S.A.
- Glycosyn
- Inbiose NV
- Medolac Laboratories
- Neolacta Lifesciences Pvt. Ltd.
- Nestle Health Science
- Royal DSM
- Royal FrieslandCampina N.V.
- ZuChem
Human Milk Oligosaccharides Industry Developments
- February 2026: Meihua Group, supported by CIRS Group, obtained the first approval for 3'-SL in China. CIRS Group stated that the approval is a significant milestone for compliant HMO ingredients in the country. (source: cirs-group.com)
- In June 2025, BENEO and WACKER partnered globally to produce and launch the HMO 2′-Fucosyllactose (2′-FL). WACKER leads precision fermentation in Europe, while BENEO manages commercialization, with first volumes supplied to European infant formula manufacturers. (Source: beneo.com)
Human Milk Oligosaccharides Market Segmentation
By Type Outlook
- 2’FL
- 3’FL
- 3’SL
- 6’SL
By Application Outlook
- Infant Formula
- Functional Food & Beverage
- Food Supplements
By Distribution Channel Outlook
- Hypermarkets & Supermarkets
- Drug Store or Pharmacy
- Online Sales Channel
- Others
By Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Human Milk Oligosaccharides Market Report Scope
| Report Attributes | Details |
| Market Size Value in 2025 | USD 292.09 million |
| Market Size Value in 2026 | USD 340.62 million |
| Revenue Forecast by 2034 | USD 1,821.29 million |
| CAGR | 22.60% from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD million and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Industry Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The global market size was valued at USD 292.09 million in 2025 and is projected to grow to USD 1,821.29 million by 2034.
The global market is expected to register a CAGR of 22.60% during 2026–2034.
Asia Pacific led the market in 2025 with 52.4% share, driven largely by the region's growing population and increasing birth rates, particularly in countries such as China and India.
Elicityl S.A., Abbott Laboratories, Biosynth Carbosynth, Dextra Laboratories Ltd., Dupont Nutrition & Biosciences, Glycosyn, BASF S.E., Glycom A/S, Nestle Health Science, Neolacta Lifesciences Pvt. Ltd., Royal DSM, Medolac Laboratories, Chr. Hansen Holding A/S, ZuChem, Inbiose NV, and Royal FrieslandCampina N.V. are among the key players in the market.
The 2’FL segment dominated the market in 2025 with 56.8% share, driven by its substantial health benefits, particularly in infant nutrition.
The infant formula segment held the largest share of 73.4% in 2025.
Download Sample Report of Human Milk Oligosaccharides(HMO) Market
Please fill out the form to request a customized copy of the research report.
